LEXINGTON, Mass.--(BUSINESS WIRE)--Nov. 19, 2014--
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that a poster
highlighting preclinical results from its Hsp90 inhibitor Drug Conjugate
(HDC) platform is being presented at the 26th EORTC-NCI-AACR
Symposium in Barcelona.
“This poster highlights our ongoing evaluation of multiple candidates
from the HDC platform. The preclinical results for our lead candidates
not only demonstrate broad activity across several tumor types, but also
the ability for HDCs to induce prolonged antitumor effects as compared
to well-established cytotoxic agents,” said Weiwen Ying, Vice President,
Discovery Chemistry at Synta. “In addition, the platform is not limited
to using traditional cytotoxic therapeutics as payloads. A number of
commonly used small molecule anticancer agents may also be incorporated,
including tyrosine kinase inhibitors, proteosome inhibitors, small
molecule immunotherapeutics, and other molecularly targeted agents. By
leveraging the preferential retention characteristic of the Hsp90
targeting arm of an HDC in tumors, intratumoral exposure and antitumor
potency for a wide array of payloads can be potentially improved. ”
“We are encouraged by the progress the team has achieved to date with
candidates arising from the HDC platform and the promise that the
platform holds for both internal development and partnerships,” said
Anne Whitaker, President and Chief Executive Officer of Synta. “We
continue to evaluate options for efficiently advancing candidates from
this platform and look forward to providing updates in the future.”
Information regarding the poster presentation is as follows:
Hsp90 Inhibitor Drug Conjugates (HDCs): Payloads and Possibilities
Abstract number: 260
Presentation: Thursday, November 20, 6:00 PM
Local Time
Presenter: Dinesh Chimmanamada, PhD, Synta
Pharmaceuticals Corp., Lexington, Massachusetts.
A copy of the poster is available at www.syntapharma.com.
About Hsp90 inhibitor Drug Conjugates (HDC)
HDCs are small-molecule drugs consisting of an Hsp90 inhibitor
(targeting moiety) joined to an anti-cancer agent (payload) via a
cleavable chemical linker optimized for controlled release of payload
drug inside cancer cells. They exploit the preferential retention of
Hsp90 inhibitors in tumors to selectively deliver anti-cancer payloads.
HDCs represent a promising new therapeutic class with the potential to
enhance the safety and efficacy of a wide range of small molecule
anti-cancer drugs.
Synta has established proof of concept for HDC lead candidates in
preclinical studies and has developed HDCs using a range of Hsp90
inhibitor moieties, cleavable linkers, and over 40 anti-cancer payloads.
The latter include cytotoxic chemotherapeutics, kinase inhibitors,
hormone therapies, immunomodulators, epigenetic modifiers, and other
small molecule anticancer agents, creating the potential for
next-generation compounds in each of these categories. Synta has filed
worldwide patent applications that include comprehensive claims covering
the HDC platform, compositions of matter, methods for identifying
therapeutically effective compounds, and methods of use of such
compounds against a wide range of diseases and conditions.
About Synta Pharmaceuticals
Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on
discovering, developing, and commercializing small molecule drugs to
extend and enhance the lives of patients with severe medical conditions,
including cancer and chronic inflammatory diseases. Synta has a unique
chemical compound library, an integrated discovery engine, and a diverse
pipeline of clinical- and preclinical-stage drug candidates with
distinct mechanisms of action and novel chemical structures. All Synta
drug candidates were invented by Synta scientists using its compound
library and discovery capabilities. For more information, please visit www.syntapharma.com.
Safe Harbor Statement
This media release may contain forward-looking statements about Synta
Pharmaceuticals Corp. Such forward-looking statements can be identified
by the use of forward-looking terminology such as "will", "would",
"should", "expects", "anticipates", "intends", "plans", "believes",
"may", "estimates", "predicts", "projects", or similar expressions
intended to identify forward-looking statements. Such statements
including statements related to the potential for HDC candidates to
demonstrate broad activity across tumor types, the potential for
prolonged antitumor effect with an HDC candidate, the potential
associated with various payloads delivered via the HDC platform, the
potential to use cytotoxic agents, tyrosine kinase inhibitors,
proteosome inhibitors, small molecule immunotherapeutics and other
molecularly targeted agents as payloads for HDC candidates, the
potential for HDC candidates to have improved intratumoral exposure and
antitumor potency, the promise of the HDC platform for internal
development and partnerships, and the potential of the HDC platform to
enhance the safety and efficacy of a wide range of small molecule
anti-cancer drugs, reflect Synta’s current views with respect to future
events and are based on assumptions and subject to risks and
uncertainties that could cause actual results to differ materially from
those expressed or implied by such forward-looking statements, including
those described in "Risk Factors" of our Form 10-K for the year ended
December 31, 2013 as filed with the Securities and Exchange Commission.
Synta undertakes no obligation to publicly update forward-looking
statements, whether because of new information, future events or
otherwise, except as required by law.
Source: Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp.
Daniel Cole, 781-541-7250
[email protected]
or
Argot
Partners
Andrea Rabney, 212-600-1494
[email protected]
or
Media:
Argot
Partners
Eliza Schleifstein, 917-763-8106
[email protected]